# MAYO CLINIC Hepatobiliary Cancer SPORE Quarterly Newsletter

https://www.mayo.edu/research/centers-programs/cancer-research/researchprograms/gastrointestinal-cancer-program/mayo-clinic-hepatobiliary-spore



GI/Pancreas/NET/Liver Cancer SPORE Investigator's Meeting

# January 11-12, 2024 Mayo Clinic, Phoenix, AZ

Drs. Mark McNiven and Lewis Roberts, MPIs of the Mayo Clinic Hepatobiliary SPORE, designed the meeting to assemble investigators from SPOREs in the following cancer areas: gastrointestinal (GI), liver, pancreatic, hyperactive RAS and neuroendocrine. NCI program staff and SPORE patient advocates with an interest in GI malignancies are also invited guests. We hope this venue will enable data sharing and will offer many new collaborative opportunities within the SPORE community.

The meeting will address the following critical areas: tumor metabolism, cancer immunology and immune microenvironment, precision therapy, and precursor lesions, early detection and interception. These sessions will endeavor to develop collaborative approaches to address key questions in the field and define promising scientific areas.

Meeting website: https://events.cancer.gov/dctd/gisporemeeting

Virtual option link for both days:

https://mcmeet.zoom.us/j/91852501218?pwd=UDV0VnISMStnd0hxZ1IzUGZMVIpGUT09

## **Congratulations Gina Razidlo, Ph.D.**

**Dr. Razidlo (DRP Awardee)** recently was promoted to an Associate Consultant II in the Department of Biochemistry and Molecular Biology.

She also has a new paper published together with Dr. Mark McNiven (SPORE PI) in Cell Reports.



## Project 4 Spotlight: Richard Vile, Ph.D.

#### Unleashing viruses aimed at killing cancer

Oncolytic viruses are a way to alert the immune system and mobilize it to kill cells infected with cancer," says Dr. Vile. "There's the direct killing of cancer cells with the virus, and then there's the major effect of immune activation. The immune system is incredibly well evolved to recognize infection, clear infection and kill all the cells around it that could be harboring infection."

In groundbreaking research, Dr. Vile's team is combining oncolytic viruses with <u>chimeric antigen receptor T-cell therapy (CAR-T cell</u> <u>therapy</u>) to target solid tumors from liver cancer. This experimental approach of loading CAR-T cells with oncolytic virus is a new way to expand CAR-T cell therapy beyond treatment for blood cancers into treatment for solid tumors.

#### Full Article:

Unleashing viruses aimed at killing cancer | Center for Regenerative Biotherapeutics (mayoclinic.org)

### **Recent Publications**


Omar L. Gutierrez-Ruiz, Katherine M. Johnson, Eugene W. Krueger, Roseanne E. Nooren, Nicole Cruz-Reyes, Carrie Jo Heppelmann, Tara L. Hogenson, Martin E. Fernandez-Zapico, **Mark A. McNiven, Gina L. Razidlo,** Ectopic expression of DOCK8 regulates lysosome-mediated pancreatic tumor cell invasion, Cell Reports, Volume 42, Issue 9, 2023, 113042, ISSN 2211-1247, <u>https://doi.org/10.1016/j.celrep.2023.113042</u>.

Neumayer C, Ng D, Requena D, Jiang CS, Qureshi A, Vaughan R, Prakash TP, Revenko A, **Simon SM**. GalNAc-conjugated siRNA targeting the DNAJB1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma. Mol Ther. 2023 Nov 21:S1525-0016(23)00613-5. doi: 10.1016/j.ymthe.2023.11.012. Epub ahead of print. PMID: 37980543.

Fiorentini G, Zironda A, Calini G, Abdalla S, Nagorney DM, Warner SG, **Smoot RL**, Behm KT, Shawki SF, Mathis KL, Vierkant RA, Larson DW, **Cleary SP**. Minimally invasive vs. open approach to the simultaneous treatment of colorectal tumors with synchronous liver metastasis: a single center, propensity-score matched analysis from Mayo clinic. HPB (Oxford). 2023 Nov;25(11):1337-1344. doi: 10.1016/j.hpb.2023.06.010. Epub 2023 Jun 24. PMID: 37626006.

Zhang C, Gudmundsdottir H, Takahashi H, Day C, Glasgow A, Wasif N, Starlinger P, Warner S, Grotz T, **Smoot R**, Truty M, **Cleary S**, Kendrick M, Nagorney D, Navin P, Halfdanarson TR, Thiels C. Accuracy of DOTATATE PET imaging in the preoperative planning of small bowel neuroendocrine tumor resection. J Surg Oncol. 2023 Dec;128(7):1072-1079. doi: 10.1002/jso.27413. Epub 2023 Aug 2. PMID: 37529970.

Lozada ME, Zhang N, Jin W, Wongjarupong N, Yang JD, Voss MM, Prasai K, Amakye DO, Harmsen WS, Chaudhary S, Bathe OF, **Borad MJ, Patel TC**, **Gores GJ**, Therneau TM, **Roberts LR**. CS-iCCA, A New Clinically Based Staging System for Intrahepatic Cholangiocarcinoma: Establishment and External Validation. Am J Gastroenterol. 2023 Dec 1;118(12):2173-2183. doi: 10.14309/ajg.00000000002258. Epub 2023 Mar 20. PMID: 36940423.



Liver SPORE Newsletter

Q4 2023

page 3

## Year In Review: Community Engagement and Diversity Council



Our SPORE's CED Council has been actively engaged with our patient advocates and communities this year. Please contact Dr. Lewis Roberts <u>roberts.lewis@mayo.edu</u> or Dr. Lionel Kankeu Fonkoua <u>KankeuFonkoua.Lionel@mayo.edu</u> to get involved!

### REMINDERS

Acknowledge the HBC SPORE P50 CA210964 in your abstracts, presentations, and publications.

### **Liver SPORE Contacts**

Mark McNiven, Ph.D., SPORE Director Mike Torbenson, M.D. Co-Director, Biospecimen & Pathology Core John Henley, Ph.D, Administrator Amanda Bedard, Administrative Assistant Lewis Roberts, M.B., Ch.B., Ph.D., SPORE Co-Director Qian Shi, Ph.D. and Chen Wang, Ph.D. Co-Directors, Biostatistics and Bioinformatics Core Fowsiyo Ahmed, M.B.B.S., Biospecimen Coordinator Images used with permission